Home >
Medicine Info >
Vymada 100 mg Tablet
Loading interface...

Vymada 100 mg Tablet

Manufactured byNOVARTIS INDIA LTD
ContainsSacubitril (49 mg) + Valsartan (51 mg)
Description
Vymada 100 mg Tablet is a combination medicine used for the prevention of cardiac symptoms in patients suffering from chronic heart failure. It reduces the risk of hospitalization and death associated with heart failure in such patients. This medicine is usually given in combination with other medicines for heart failure.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Side effects

Major & minor side effects for Vymada 100 mg Tablet

  • Dizziness
  • Stomach pain
  • Nausea
  • Diarrhea
  • Decreased blood pressure
  • Headache
  • Fainting
  • Cough
  • Weight gain
  • Increased thirst
  • Unusual tiredness and weakness

Uses of Vymada 100 mg Tablet

What is it prescribed for?

  • Chronic heart failure
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The amount of time required for this medicine to show its action is not clinically established.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is this a habit forming medicine?
    No habit-forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to valsartan, sacubitril, or any other inactive ingredients present in the formulation.

Aliskiren

Coadministration of aliskiren and this combination medicine is not recommended due to the increased risk of serious adverse effects. This risk is especially higher in the elderly population and in patients with diabetes and kidney diseases.

Angioedema

This medicine is not recommended for use in patients with a known history of angioedema caused due to hereditary causes, or an unknown cause or associated with the use of medicines like an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB). It is recommended not to take ACE inhibitors within 36 hours of switching to or from this combination medicine.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless necessary. The risks and benefits should be discussed with the doctor before taking this medicine.
General warnings

Renal artery stenosis

This medicine should be used with caution in patients with renal artery stenosis due to the increased risk of severe adverse effects. Close monitoring of blood urea and serum creatinine levels is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Hyperkalemia

This medicine may increase potassium levels in the blood (hyperkalemia). This may cause serious side effects such as fatal cardiac rhythm irregularities. It is advised to avoid potassium-rich foods (potatoes, bananas) and other medicines that may increase potassium levels (potassium-sparing diuretics and potassium supplements) during treatment with this medicine.

Use in children

This medicine is not recommended for use in children since the safety and efficacy of use are not clinically established.

Driving and operating machines

This medicine may cause dizziness or fatigue in some patients. It is advised that you do not perform any activities that require high mental alertness like driving a vehicle or operating machinery if you experience any of these symptoms during treatment with this medicine.

Angioedema

This medicine is not recommended for use in patients with a known history of angioedema due to the increased risk of worsening of the patient's condition. Report any symptoms such as swelling of the face or lips, difficulty swallowing, or difficulty breathing to the doctor immediately. Replacement with a suitable alternative may be required based on the clinical condition.

Diabetes

This medicine should be used with caution in patients suffering from diabetes due to the increased risk of altered blood sugar levels. Close monitoring of blood sugar levels is recommended for such patients. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine

Insulin

Dexamethasone

Angiotensin converting enzyme inhibitors (ACEI's)

Nonsteroidal anti-inflammatory medicines

Spironolactone

Disease interactions

Renal/Liver Disease

This medicine should be used with caution in patients with kidney or liver impairment due to the risk of severe adverse effects. Close monitoring of the clinical condition, appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.

Hypotension

This medicine should be used with extreme caution in patients with low blood pressure, decreased sodium levels or volume depletion. Sodium or volume depletion should be corrected before starting treatment with this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be necessary based on the clinical condition of the patient.
Food interactions
It is advised to avoid potassium containing foods and supplements while taking this medicine due to the increased risk of weakness, confusion, irregular heartbeat, etc. Consult the doctor immediately in case of any unusual symptoms. Your dietitian/doctor may suggest appropriate changes in your diet based on your clinical condition.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take this medicine exactly as advised by your doctor. Do not take in larger or smaller amounts than prescribed. Consult the doctor if you experience any undesirable side effects. Ensure that the treatment course is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

May cause sleepiness

How it works
Sacubitril works by inhibiting an enzyme neprilysin that degrades certain substances necessary for lowering the blood pressure in the body. Valsartan works by preventing the narrowing of blood vessels and promoting smooth blood flow.
Legal Status

Unknown

Approved

Unknown

Approved

Classification

Category

Angiotensin receptor blockers and neprilysin inhibitors

Schedule

Schedule H

[Internet]. Pharma.us.novartis.com. 2019 [cited 28 May 2019]. Available from:

https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/entresto.pdf

Entresto 49 mg/51 mg film-coated tablets - Summary of Product Characteristics (SmPC) - (eMC) [Internet]. Medicines.org.uk. 2019 [cited 28 May 2019]. Available from:

https://www.medicines.org.uk/emc/product/7752/smpc

Azmarda Tablets [Internet]. CiplaMed. 2019 [cited 28 May 2019]. Available from:

https://ciplamed.com/content/azmarda-tablets

[Internet]. Ebs.tga.gov.au. 2019 [cited 28 May 2019]. Available from:

https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-01107-1&d=201905281016933
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 7 Jun 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.